Herceptin Biosimilar Market, By Indication (Breast Cancer, Gastric Cancer, Others), By Distribution Channel (Hospitals, Oncology Centers, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Description

Herceptin Biosimilar Market is estimated to be valued at USD 5.27 Bn in 2026 and is expected to reach USD 10.07 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 5.27 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.70%	2033 Value Projection:	USD 10.07 Bn

Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.

Market Dynamics

Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Herceptin biosimilar market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.

Market Segmentation

By Indication
- Breast Cancer
- Gastric Cancer
- Others
By Distribution Channel
- Hospitals
- Oncology Centers
- Others
Global Herceptin Biosimilar Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Amgen Inc.
- AryoGen Biopharma
- Biocon Limited
- Celltrion Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Accord Healthcare Ltd
- Gedeon Richter Plc
- Genor Biopharma Company Ltd
- Mabion SA
- Mylan N.V
- Roche Holding AG
- Samsungbioepis Co., Ltd.

Product Code: CMI4258

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Herceptin Biosimilar Market, By Indication, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Gastric Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Herceptin Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Herceptin Biosimilar Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Amgen Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- AryoGen Biopharma
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Biocon Limited
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Celltrion Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Pfizer Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Merck & Co., Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Accord Healthcare Ltd
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Gedeon Richter Plc
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Genor Biopharma Company Ltd
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Mabion SA
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Mylan N.V
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Roche Holding AG
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Samsungbioepis Co,.Ltd.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Analyst Views

8. Section

References
Research Methodology
About Us